Ardelyx, Inc. (ARDX)
Ardelyx, Inc. (ARDX) is a biotechnology company focused on developing and commercializing novel treatments for cardio-renal and gastrointestinal diseases. Founded to address unmet medical needs, Ardelyx's portfolio includes therapies targeting conditions such as chronic kidney disease, constipation, and other gastrointestinal disorders.
Company News
Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Ardelyx (NASDAQ:ARDX) in the last three months. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullis...
Ardelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to buy? Here are some of the most active under $5 to watch. The post Penny Stocks To Buy Now? 5 Under $5 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.